Emergent BioSolutions Files 8-K
Ticker: EBS · Form: 8-K · Filed: Aug 30, 2024 · CIK: 1367644
| Field | Detail |
|---|---|
| Company | Emergent Biosolutions Inc. (EBS) |
| Form Type | 8-K |
| Filed Date | Aug 30, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, regulatory
TL;DR
Emergent BioSolutions dropped an 8-K, could be anything from new deals to financial updates.
AI Summary
Emergent BioSolutions Inc. filed an 8-K on August 30, 2024, reporting events as of August 29, 2024. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. Specific details regarding the nature of these events or any financial figures were not provided in the excerpt.
Why It Matters
This 8-K filing indicates that Emergent BioSolutions is disclosing material information to the SEC, which could impact investors' understanding of the company's current status.
Risk Assessment
Risk Level: medium — 8-K filings can contain significant corporate news, but the provided excerpt lacks specific details to assess the immediate impact.
Key Numbers
- 001-33137 — SEC File Number (Identifies the company's filing with the SEC)
- 14-1902018 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Emergent BioSolutions Inc. (company) — Registrant
- August 29, 2024 (date) — Date of earliest event reported
- August 30, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Gaithersburg, Maryland (location) — Principal executive offices
FAQ
What specific events are being disclosed under Regulation FD?
The provided excerpt does not specify the nature of the Regulation FD disclosure.
What are the 'Other Events' being reported by Emergent BioSolutions?
The excerpt does not detail the specific 'Other Events'.
Are there any significant financial statements or exhibits included with this filing?
The filing indicates 'Financial Statements and Exhibits' are included, but their content is not detailed in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on August 29, 2024.
What is Emergent BioSolutions' principal executive office address?
The principal executive offices are located at 300 Professional Drive, Gaithersburg, Maryland 20879.
Filing Stats: 598 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-08-29 20:26:56
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share EBS New York Stock
Filing Documents
- ebs-20240829.htm (8-K) — 29KB
- pressrelease_08292024.htm (EX-99.1) — 16KB
- imagea.jpg (GRAPHIC) — 7KB
- 0001367644-24-000155.txt ( ) — 186KB
- ebs-20240829.xsd (EX-101.SCH) — 2KB
- ebs-20240829_lab.xml (EX-101.LAB) — 22KB
- ebs-20240829_pre.xml (EX-101.PRE) — 13KB
- ebs-20240829_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On August 29, 2024, Emergent BioSolutions Inc. ("Emergent") issued a press release containing the announcement described below. A copy of this press release is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference. The information contained in this Item 7.01 shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing, under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Other Events
Item 8.01. Other Events. On August 29, 2024, Emergent announced U.S. Food and Drug Administration approval of Emergent's supplemental Biologics License Application for the expansion of the indication for ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Live), to include immunization for the prevention of mpox disease in individuals determined to be at high risk for mpox infection. This approval follows Emergent's announcement that it filed an Expression of Interest with the World Health Organization ("WHO") for the WHO's assessment of ACAM2000 vaccine to be added as an Emergency Use Listing in connection with the mpox outbreak.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press release issued by Emergent BioSolutions Inc. on August 29, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EMERGENT BIOSOLUTIONS INC. Dated: August 29, 2024 By: /s/ RICHARD S. LINDAHL Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer